Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin

Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin: an interventional prospective randomised placebo-controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN76354426

Enrollment

Registered

2010-03-03

Start date

2009-12-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary tract infections (UTIs) Urological and Genital Diseases Other disorders of urinary system

Interventions

Patients will be randomised to receive: 1. Intravesical instillations of sodium HA (high molecular weight) 1.6% and CS 2.0% dose 50 ml of saline 2. Intravesical instillations of 50 ml saline (controls

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Women aged 18 - 80 years old 2. Spontaneous urination 3. Greater than three uncomplicated UTIs/previous year 4. Free from UTIs at the beginning of study 5. No ongoing prophylactic antibiotic treatment 6. Able to provide informed consent

Exclusion criteria

Exclusion criteria: 1. Greater than 50 ml residual urine 2. Neurological bladder disease 3. Known neoplasia, urinary stone or urinary tract abnormality 4. Use of indwelling catheter 5. Renal insufficiency 6. Diabetes 7. Current corticosteroid use 8. Pregnancy 9. Immunosuppressive disease

Design outcomes

Primary

Measure	Time frame
Rate of UTIs per patient per year. Outcome assessment at 1, 3, 6, 9 and 12 months.	—

Secondary

Measure	Time frame
Outcome assessment at 1, 3, 6, 9 and 12 months: 1. Time to UTI recurrence 2. Rate of adverse events	—

Countries

Italy

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026